TARDBP and tauopathy: Because many cases of Alzheimer’s disease (AD) also possess TDP-43 pathology42–46, cryptic peptide biomarkers would be helpful in distinguishing ‘pure AD’ exhibiting only canonical pathologies of β-amyloidosis and tauopathy from mixed (or multiple)-etiology dementia, which probably warrant different treatment strategies.